SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-136095
Filing Date
2023-05-04
Accepted
2023-05-04 17:18:08
Documents
12
Period of Report
2023-05-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d336282d8k.htm   iXBRL 8-K 32746
  Complete submission text file 0001193125-23-136095.txt   156250

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA bbio-20230503.xsd EX-101.SCH 2855
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE bbio-20230503_lab.xml EX-101.LAB 17993
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bbio-20230503_pre.xml EX-101.PRE 11264
6 EXTRACTED XBRL INSTANCE DOCUMENT d336282d8k_htm.xml XML 3348
Mailing Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304
Business Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304 (650) 391-9740
BridgeBio Pharma, Inc. (Filer) CIK: 0001743881 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38959 | Film No.: 23889999
SIC: 2834 Pharmaceutical Preparations